-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rezafungin Acetate in Fungal Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rezafungin Acetate in Fungal Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rezafungin Acetate in Fungal Infections Drug Details: Rezafungin acetate (Rezzayo)...
-
Product Insights
Giant Cell Arteritis Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Giant Cell Arteritis Global Clinical Trials Review, H2, 2017" provides an overview of Giant Cell Arteritis clinical trials scenario. This report provides top line data relating to the clinical trials on Giant Cell Arteritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2027
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of proliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. B-cell lymphomas comprise approximately 85% of all NHL cases diagnosed in the US, and are a diverse group of blood cancers that arise in the B-cells. This report focuses on the four NHL subtypes that represent the greatest commercial opportunities for drug developers...
-
Track & Monitor
CMO Scorecard – Outsourcing of NDA Approvals and CMO Performance – 2019 PharmSource Edition
This report is the 9th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.
-
Sector Analysis
Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EU
Market access of oncology medicines is increasingly challenging due to the rising cost of new and innovative medicines, more stringent scientific and value assessments and economic pressures on national budgets and health systems. Although, 5EU markets have implemented patient access schemed to ensure early access to innovative oncology medicines with high unmet need, the increasing requirements for improved clinical benefits and better cost-effectiveness of medicines has resulted in more stringent pricing and reimbursement of medicines leading to access issues such...
-
Sector Analysis
Digital Landscape: Asthma
The Digital Landscape Asthma report analyzes digital activities undertaken by pharma in support of therapies for asthma
-
Track & Monitor
CMO Scorecard – Outsourcing of NDA Approvals and CMO Performance – 2020 PharmSource Edition
This report is the 10th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.